SINO BIOPHARM News

SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - CATEGORY 1 INNOVATIVE DRUG "TQA3038 (siRNA)" COMPLETED PHASE I CLINICAL STUDY

Apr 25 18:03

SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME

Apr 19 18:09

SINO BIOPHARM: NEXT DAY DISCLOSURE RETURN

Apr 19 17:02

SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - CATEGORY 1 INNOVATIVE DRUG "ROVADICITINIB (TQ05105)" OBTAINED POSITIVE RESULTS IN KEY CLINICAL RESEARCH FOR REGISTRATION

Apr 18 19:27

SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME

Apr 17 17:09

SINO BIOPHARM: NEXT DAY DISCLOSURE RETURN

Apr 16 16:35

SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME

Apr 15 16:59

SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME

Apr 12 17:22

SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - PRESENTATION OF THE PHASE II CLINICAL STUDY DATA ON KRAS G12C INHIBITOR "GARSORASIB TABLET (D-1553)"

Apr 11 06:04

SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - DATA OF 6 STUDIES REGARDING "ANLOTINIB HYDROCHLORIDE CAPSULES", "TQB2916 (CD40 AGONIST)" AND "FHND6091 (PROTEASOME INHIBITOR)" WERE PRESENTED AT 2024 AACR

Apr 10 20:02

SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME

Apr 8 17:52

SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - ENTER INTO STRATEGIC PARTNERSHIP WITH BOEHRINGER INGELHEIM ON INNOVATIVE ONCOLOGY PORTFOLIO IN CHINA

Apr 8 07:59

SINO BIOPHARM: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2024

Apr 2 09:56

SINO BIOPHARM: FINAL DIVIDEND FOR 2023

Mar 28 17:03

SINO BIOPHARM: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023

Mar 28 16:31

SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF "IOPROMIDE INJECTION"

Mar 25 06:11

SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - UPDATE ON DEVELOPMENT PROGRESS OF MASH PRODUCTS "LANIFIBRANOR" AND "TQA2225"

Mar 15 17:56

SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - DATA OF PHASE II CLINICAL STUDY OF KRAS G12C INHIBITOR "GARSORASIB TABLET (D-1553)" WILL BE PRESENTED AT 2024 AACR

Mar 13 16:34

SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - DATA OF 5 STUDIES REGARDING "ANLOTINIB HYDROCHLORIDE CAPSULES" AND "TQB2916 (CD40 AGONIST)" WILL BE PRESENTED AT 2024 AACR

Mar 11 18:56

SINO BIOPHARM: NOTIFICATION OF BOARD MEETING

Mar 1 16:34